Because there is a solid pharmacological rationale based on positive interactions between
long‐acting muscarinic receptor antagonists (LAMAs) and long‐acting β‐agonists (LABAs) …

Combining a long-acting β 2-agonist (LABA) with a long-acting anti-muscarinic agent
(LAMA) provides synergistic benefit on airway smooth muscle relaxation, which may have …

Objective Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs)
are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) …

Background The wide availability of long-acting muscarinic antagonist (LAMA)/long-acting
β2-agonist (LABA) fixed-dose combinations (FDCs) in the absence of head-to-head …

ABSTRACT Introduction: Long-acting β2-adrenoceptor (β2-AR) agonists (LABAs) plus long-
acting muscarinic antagonists (LAMAs) is the cornerstone for treating chronic obstructive …

Despite several long-acting β 2-adrenoceptor agonist (LABA)/long-acting muscarinic
antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved for the treatment …

Chronic obstructive pulmonary disease (COPD) represents a significant cause of global
morbidity and mortality, with a substantial economic impact. Recent changes in the Global …

Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting
muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the …

Introduction Accumulated high-quality data from randomised controlled trials (RCTs)
indicate that long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) …

Purpose Dual bronchodilator therapy with a long-acting muscarinic antagonist (LAMA) and a
long-acting β 2-agonist (LABA) is recommended in the pharmacological management of …